Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the therapeutic
method with the most potent anti-leukemic activity mediated by the graft versus leukemia …

Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers
to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the …

Acute graft-vs-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic
stem cell transplantation (HSCT), leading to a significant morbidity and mortality. GVHD …

Nonmyeloablative allogeneic stem cell transplantation has recently been explored as a
safer alternative to conventional high-dose transplant regimens. Although a high incidence …

Background The treatment of chronic granulomatous disease with conventional allogeneic
hematopoietic stem-cell transplantation carries a high risk of serious complications and …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from the
clonal expansion of a transformed multipotent hematopoietic stem cell. CML is a biphasic …

Previous trials of allogeneic bone marrow transplantation (BMT) in patients with multiple
myeloma (MM) have demonstrated high response rates but also high transplantation-related …

The most common cause of post-transplant mortality in patients with hematological
malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy …

We investigated the feasibility of unrelated stem cell transplantation in 21 patients with
advanced stage II/III multiple myeloma after a reduced-intensity conditioning regimen …

Langerhans cells (LC) and other antigen-presenting cells are believed to be critical in
initiating graft versus host responses that influence the outcome of allogeneic hematopoietic …